How Mounjaro is reshaping prescription weight care

Mounjaro is prescribed in the US for adults with type 2 diabetes and has drawn attention for its impact on weight. Here is how the drug works and what patients should know.

Mounjaro is a prescription injection from Eli Lilly that is approved in the US for adults with type 2 diabetes to improve blood sugar when used with diet and exercise, according to the FDA prescribing information as of 11/2023FDA, 11/2023.

Updated: 05/19/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

At a Glance

• Product: Mounjaro
• Category: Prescription injectable medicine
• Brand/Manufacturer: Eli Lilly and Company
• Main Use Cases: Blood sugar control in adults with type 2 diabetes
• Availability: Prescription only in the US
• Key Markets: United States and other selected countries

What Mounjaro Is and How It Works

Mounjaro is the brand name for tirzepatide, a once weekly injectable medicine in a class called GIP and GLP-1 receptor agonist, described by Eli Lilly as a dual GIP and GLP-1 receptor agonist in its US prescribing information as of 11/2023Eli Lilly, 11/2023.

The FDA states that Mounjaro is indicated to improve glycemic control in adults with type 2 diabetes when used with diet and exercise and that it is not indicated for use in people with type 1 diabetesFDA, 11/2023.

According to Eli Lilly, tirzepatide works by activating GIP and GLP-1 receptors, which are involved in regulating insulin secretion and blood sugar in response to mealsEli Lilly Medical, 10/2023.

How patients take Mounjaro

The official prescribing information describes Mounjaro as a once weekly subcutaneous injection that can be given in the abdomen, thigh, or upper arm, with or without meals, on the same day each weekEli Lilly, 11/2023.

The FDA label explains that treatment is usually started at a low dose, with stepwise increases over time based on blood sugar response and tolerability, under the supervision of a health care providerFDA, 11/2023.

Weight effects reported in diabetes trials

In clinical studies in adults with type 2 diabetes, the FDA label notes that people taking tirzepatide experienced reductions in body weight along with blood sugar improvements, although weight loss is not the primary approved indicationFDA, 11/2023.

Eli Lilly reports on its medical site that weight changes in diabetes trials were dose dependent and occurred over several weeks of continued use, highlighting that individual results vary and that lifestyle measures remained importantEli Lilly Medical, 10/2023.

Why Mounjaro Matters for Consumers and Industry

Major US outlets including The New York Times have reported that Mounjaro has attracted attention because of its impact on both blood sugar control and weight in adults with type 2 diabetes since its FDA approval in 2022New York Times, 06/09/2023.

CNN Health noted that many US patients ask their doctors about weight related benefits when discussing Mounjaro, even though the drug is approved specifically for type 2 diabetes managementCNN, 07/10/2023.

For individual consumers, this interest translates into questions about eligibility, long term safety, insurance coverage, and how a weekly injection fits into daily life, as described by Consumer Reports in its overview of new diabetes drugsConsumer Reports, 09/2023.

Clinical oversight and medical guidance

The American Diabetes Association standards of care stress that medications like Mounjaro must be part of a comprehensive plan that includes nutrition, physical activity, and regular monitoring, tailored to each patientDiabetes Care, 12/2022.

Mayo Clinic patient guidance emphasizes that people should not adjust doses or stop medicines such as tirzepatide without their clinician, and should review other prescriptions to lower risks like low blood sugar when drugs are combinedMayo Clinic, 08/2023.

Safety, side effects, and warnings

The FDA prescribing information carries a boxed warning that medicines like tirzepatide caused thyroid C-cell tumors in rodents, and that Mounjaro is not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2FDA, 11/2023.

Common side effects listed by the FDA include nausea, vomiting, diarrhea, decreased appetite, and abdominal pain, and the label notes that these gastrointestinal events are usually mild to moderate and tend to lessen over time for many patientsFDA, 11/2023.

Mounjaro in the US and Global Market

Reuters reported that US demand for newer injectable diabetes medicines, including tirzepatide under the Mounjaro brand, has been strong, contributing to tight supplies in some periods as manufacturers expand capacityReuters, 08/08/2023.

The Wall Street Journal described how Mounjaro is part of a broader shift toward incretin based therapies in diabetes care, alongside products such as Ozempic and Wegovy from Novo Nordisk, which also act on GLP-1 receptorsWall Street Journal, 06/30/2023.

In the United States, the drug is available only by prescription, and coverage depends on individual health plans, with insurers often applying prior authorization for newer diabetes injectables, according to guidance summarized by Kaiser Family FoundationKFF, 07/2023.

• Once weekly injectable for adults with type 2 diabetes in the US.
• Works on GIP and GLP-1 receptors to help lower blood sugar.
• May lead to weight reduction in diabetes studies, but use is for glycemic control.
• Prescription only, with safety warnings and need for clinical oversight.
• Part of a larger trend toward incretin based therapies in diabetes care.

Frequently Asked Questions About Mounjaro

Is Mounjaro approved in the US for weight loss?
The FDA approval for Mounjaro is for improving blood sugar in adults with type 2 diabetes, and the label states that it is not indicated for weight lossFDA, 11/2023.

Can people without diabetes use Mounjaro?
The FDA label describes use in adults with type 2 diabetes, and people without diabetes should not use the medicine unless a clinician prescribes it for an approved indicationFDA, 11/2023.

How often is Mounjaro injected?
The prescribing information states that Mounjaro is injected once weekly on the same day each week, with or without meals, in the abdomen, thigh, or upper armEli Lilly, 11/2023.

Eli Lilly and Company, based in the United States, develops and markets Mounjaro as part of its portfolio of diabetes therapies for adult patients worldwideEli Lilly, 10/2023.

Mounjaro is associated with Eli Lilly and Company, whose shares trade on the New York Stock Exchange under the ticker LLY and whose global identifier for investors includes the ISIN US5324571083Eli Lilly Investor, 10/2023.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.